Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | REN | P00797 | 3/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.39 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15619034 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP2C19SYKALDH1A1 | |
| SCHEMBL7294934 | 0.92 | CYP3A4 (0.43) | CYP3A4CYP2C9CYP2C19SYKALDH1A1 | |
| SCHEMBL15627206 | 0.91 | AAK1 (0.45) | CYP3A4CYP2C9CYP2C19SYKALDH1A1 | |
| SCHEMBL15627205 | 0.91 | AAK1 (0.45) | CYP3A4CYP2C9CYP2C19SYKALDH1A1 | |
| SCHEMBL17263354 | 0.90 | POLB (0.39) | CYP3A4CYP2C9CYP2C19SYKALDH1A1 | |
| SCHEMBL16983171 | 0.90 | POLB (0.39) | CYP3A4CYP2C9CYP2C19SYKALDH1A1 | |
| SCHEMBL18634622 | 0.89 | AAK1 (0.43) | CYP3A4CYP2C9CYP2C19SYKPOLB | |
| SCHEMBL7037199 | 0.86 | REN (0.44) | CYP3A4CYP2C9CYP2C19SYKPOLB | |
| SCHEMBL7037201 | 0.86 | REN (0.44) | CYP3A4CYP2C9CYP2C19SYKPOLB | |
| SCHEMBL18634702 | 0.81 | AAK1 (0.44) | CYP3A4CYP2C9CYP2C19SYKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2897960-B1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS NOTCH INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-03 | — | — | EP | disclosed |
| EP-2897960-B1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS NOTCH INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-03 | — | — | EP | disclosed |
| US-9249157-B2 | Tricyclic heterocycle compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249157-B2 | Tricyclic heterocycle compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249157-B2 | Tricyclic heterocycle compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150246930-A1 | TRICYCLIC HETEROCYCLE COMPOUNDS | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2015-09-03 | — | — | US | disclosed |
| US-20150246930-A1 | TRICYCLIC HETEROCYCLE COMPOUNDS | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2015-09-03 | — | — | US | disclosed |
| US-20150246930-A1 | TRICYCLIC HETEROCYCLE COMPOUNDS | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2015-09-03 | — | — | US | disclosed |
| EP-2897960-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS NOTCH INHIBITORS | Bristol-Myers Squibb Company (US) | 2015-07-29 | — | — | EP | disclosed |
| WO-2014047390-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS NOTCH INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-27 | — | — | WO | disclosed |
| WO-2014047390-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS NOTCH INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246930-A1 | TRICYCLIC HETEROCYCLE COMPOUNDS | RCOR3, NR4A3, NCOA3 | CYP3A4 1330/4885CYP2C9 1251/4885CYP2C19 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.